BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30774597)

  • 1. PD-1/PD-L1 Inhibitors in Cervical Cancer.
    Liu Y; Wu L; Tong R; Yang F; Yin L; Li M; You L; Xue J; Lu Y
    Front Pharmacol; 2019; 10():65. PubMed ID: 30774597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
    Jiménez-Lima R; Arango-Bravo E; Galicia-Carmona T; Lino-Silva LS; Trejo-Durán GE; Alvarado-Silva C; Castañeda-Renderos OH; Vanoye-Carlo EG; Torre CF; Dueñas-González A; Cetina-Pérez L
    Rev Invest Clin; 2020; 72(4):231-238. PubMed ID: 33064705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
    Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
    Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab for advanced cervical cancer: safety and efficacy.
    De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
    [No Abstract]   [Full Text] [Related]  

  • 7. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
    Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ;
    N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
    Saglam O; Conejo-Garcia J
    Integr Cancer Sci Ther; 2018; 5(2):. PubMed ID: 29955379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
    Peng H; He X; Wang Q
    Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date.
    Vachhani P; Chen H
    Onco Targets Ther; 2016; 9():5855-5866. PubMed ID: 27713639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.
    Ge Y; Zhang Y; Zhao KN; Zhu H
    Drug Des Devel Ther; 2022; 16():3055-3070. PubMed ID: 36110399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
    Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
    Liang J; Li M; Sui Q; Hu Z; Bian Y; Huang Y; Zhan C; Jiang W; Wang Q; Tan L
    Transl Lung Cancer Res; 2020 Aug; 9(4):1302-1323. PubMed ID: 32953506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.
    Li R; Liu Y; Yin R; Yin L; Li K; Sun C; Zhou Z; Li P; Tong R; Xue J; Lu Y
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1432-1441. PubMed ID: 33713744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.